Repligen needs the autism community's support

[Guest guest]

Repligen needs your support........

Whether or not you have a child who has benefitted from secretin treatment,

Repligen is asking you to step forward now and decry the effort by Reuters to

undermine parents as suitable judges of their autistic child's response to

drug treatment.

As many of you are aware, Repligen announced preliminary findings in their

multi-site, phase 2 secretin trial yesterday, April 4, '01. This was

followed by a very contradictory response from the financial world with Dow

reporting from the favorable viewpoint (parents correctly identified drug

treated children over placebo treated) and Reuters chosing to paint a very

negative " failure to meet end point " picture. Like many other folks, we were

stunned by this warped portrayal of what we view as a very successful and

FIRST EVER Phase 2 clinical trial in autism. As some have already noted,

Repligen has taken a very undeserved hit on Wall St. because of this

irresponsible reporting by Reuters.

Please take a moment to respond to this unfair and arbitrary judgement. We

are asking anyone who supports research aimed at therapeutic drug development

for this population to take a moment to write a brief e-mail to the

following editors at Reuters:

.Howell@... and .Luxenberg@...

Your contribution to mounting this timely response is greatly appreciated.

LeGendre